Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | RAD52 | P43351 | 1/20 | 1.00 |
| ▸ | UBE2N | P61088 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | GMNN | O75496 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | THPO | P40225 | 1/20 | 0.50 |
| ▸ | MTOR | P42345 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydroxystilbamidine SCHEMBL10621745 | 1.00 | POLB (1.00) | POLBKDM4EMAPTRAD52UBE2N | |
| Hydroxystilbamidine SCHEMBL10621740 | 1.00 | POLB (1.00) | POLBKDM4EMAPTRAD52UBE2N | |
| Stilbamidine SCHEMBL20787646 | 0.88 | POLB (0.78) | POLBKDM4EMAPTRAD52UBE2N | |
| Stilbamidine SCHEMBL3934275 | 0.88 | POLB (0.78) | POLBKDM4EMAPTRAD52UBE2N | |
| Hydroxystilbamidine SCHEMBL3338013 | 0.87 | KDM4E (0.77) | POLBKDM4EMAPTRAD52UBE2N | |
| Hydroxystilbamidine SCHEMBL17224190 | 0.87 | KDM4E (0.77) | POLBKDM4EMAPTRAD52UBE2N | |
| Hydroxystilbamidine SCHEMBL26114123 | 0.87 | KDM4E (0.77) | POLBKDM4EMAPTRAD52UBE2N | |
| Hydroxystilbamidine SCHEMBL31614578 | 0.85 | KDM4E (0.72) | POLBKDM4EMAPTRAD52UBE2N | |
| Hydroxystilbamidine SCHEMBL29439031 | 0.85 | KDM4E (0.72) | POLBKDM4EMAPTRAD52UBE2N | |
| Hydroxystilbamidine SCHEMBL108492 | 0.85 | KDM4E (0.72) | POLBKDM4EMAPTRAD52UBE2N |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-8026285-B2 | Control release of biologically active compounds from multi-armed oligomers | BEZWADA BIOMEDICAL, LLC (US) | 2011-09-27 | — | — | US | claimed |
| US-20090076174-A1 | CONTROL RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS FROM MULTI-ARMED OLIGOMERS | BEZWADA BIOMEDICAL, LLC (US) | 2009-03-19 | — | — | US | claimed |
| JP-2003514875-A | — | — | 2003-04-22 | — | — | JP | claimed |
| EP-1231948-A1 | A PROPELLANT FREE SPRAY-ON SKIN PATCH COMPOSITION FOR IMPROVING WOUND HEALING AND FOR DRUG ADMINISTRATION | Ever Power Holding Inc. (VG) | 2002-08-21 | — | — | EP | claimed |
| WO-2001037890-A1 | A PROPELLANT FREE SPRAY-ON SKIN PATCH COMPOSITION FOR IMPROVING WOUND HEALING AND FOR DRUG ADMINISTRATION | EVER POWER HOLDING INC (VG) | 2001-05-31 | — | — | WO | claimed |
| US-6224848-B1 | Pharmaceuticals providing diagnosis and selective tissue necrosis using Mossbauer absorber atom | MILLS RANDELL L (US) | 2001-05-01 | — | — | US | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| EP-3356440-B1 | HYDROPHOBIC HIGHLY BRANCHED CARBOHYDRATE POLYMERS | PURDUE RESEARCH FOUNDATION (US) | 2024-06-05 | — | — | EP | disclosed |
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-11573224-B2 | Methods of detection using X-ray fluorescence | ICAGEN, LLC (US) | 2023-02-07 | — | — | US | disclosed |
| US-20220257770-A1 | HYDROPHOBIC HIGHLY BRANCHED CARBOHYDRATE POLYMERS | PURDUE RESEARCH FOUNDATION (US) | 2022-08-18 | — | — | US | disclosed |
| US-20210290771-A1 | ENGINEERED RECEPTOR/LIGAND SYSTEM FOR DELIVERY OF THERAPEUTIC AGENTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2021-09-23 | — | — | US | disclosed |
| WO-1989003208-A1 | POLYENE MACROLIDE PRE-LIPOSOMAL POWDERS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1989-04-20 | — | — | WO | disclosed |
| US-4812312-A | ADMINISTERING BY INJECTION TO TREAT SYSTEMIC FUNGAL INFECTIONS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 1989-03-14 | — | — | US | disclosed |
| WO-1988006440-A2 | LIPOSOME-INCORPORATED NYSTATIN | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1988-09-07 | — | — | WO | disclosed |
| US-4632981-A | Human antithrombin III | GENENTECH, INC. (US) | 1986-12-30 | — | — | US | disclosed |
| US-4517294-A | CLONING BVEHICLES FOR DNA SEQUENCE | GENENTECH, INC. (US) | 1985-05-14 | — | — | US | disclosed |
| EP-0090505-A2 | Human antithrombin III, DNA sequences therefor, expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby, a process for expressing human antithrombin III, and pharmaceutical compositions comprising it | GENENTECH, INC. (US) | 1983-10-05 | — | — | EP | disclosed |
| US-3946734-A | APPARATUS FOR CONTROLLING THE RELEASE OF A DRUG | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF STATE (US) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076174-A1 | CONTROL RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS FROM MULTI-ARMED OLIGOMERS | MME, CTSA, ALG1 | POLB 1563/4885KDM4E 3828/4885MAPT 869/4885 |
| US-20220257770-A1 | HYDROPHOBIC HIGHLY BRANCHED CARBOHYDRATE POLYMERS | HACD3, ALG1, HACD2 | POLB 3423/4885KDM4E 4796/4885MAPT 1847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.